Fig. 3From: The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysisForest plot describing the association between the tolerability and therapeutic regimens (NIVO1 + IPI3 vs NIVO3 + IPI1). a any grade TRAEs, b grade 3 or higher TRAEs, c any grade TRAEs leading to discontinuation of treatmentBack to article page